Anxiety Disorders - Viable Indication for Antipsychotics Companies
From Drug Week - Jan 09, 2009
2009 JAN 9 - (NewsRx.com) -- Research and Markets has announced the
addition of the "Anxiety Disorders - Viable Indication for
Antipsychotics Companies" report to their offering. Despite forming
the mainstay of pharmacological treatment of anxiety disorders,
response rates to serotonergic-based treatments are often less than
robust. As such, physicians are increasingly looking towards novel drugs.
"People Who experience mood swings, fear, voices and visions"